Intranasal administration of RA 27/3 rubella virus vaccine. A clinical trial in young adults

Jan E. Paradise, Deborah Nemorofsky, George R. Huggins, Steven J. Sondheimer, Stanley A. Plotkin

Research output: Contribution to journalArticle

Abstract

Of the vaccines and inoculation routes studied for the prevention of rubella, only the RA27/3 vaccine, administered intranasally, has the ability to stimulate a humoral antibody pattern very similar to that evoked by wild rubella infection. Because information about intranasal (IN) vaccination has only been obtained using the RA 27/3 vaccine manufactured in Europe, we conducted a trial of IN vaccination among young adults using Meruvax II which is manufactured in the USA. Of 597 family planning clinic patients screened in 1980-1981, 71 (11.9%) were susceptible to rubella; forty-one subjects were randomly assigned to receive IN or subcutaneous (SC) vaccine. All 20 SC vaccinees, but only 8/21 (38%) IN vaccinees, were successfully immunized. We conclude that standard doses of commercially available RA 27/3 vaccine are insufficient for IN immunization against rubella. Additional study of the dose-response relationship is needed if IN vaccination is to be recommended.

Original languageEnglish (US)
Pages (from-to)75-78
Number of pages4
JournalJournal of Adolescent Health Care
Volume5
Issue number2
DOIs
StatePublished - 1984
Externally publishedYes

Fingerprint

Rubella Vaccine
Rubella virus
Intranasal Administration
Rubella
Young Adult
Vaccines
Clinical Trials
Vaccination
Family Planning Services
Immunization
Antibodies
Infection

Keywords

  • Immunization
  • Rubella prevention and control
  • Rubella vaccine

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Public Health, Environmental and Occupational Health

Cite this

Intranasal administration of RA 27/3 rubella virus vaccine. A clinical trial in young adults. / Paradise, Jan E.; Nemorofsky, Deborah; Huggins, George R.; Sondheimer, Steven J.; Plotkin, Stanley A.

In: Journal of Adolescent Health Care, Vol. 5, No. 2, 1984, p. 75-78.

Research output: Contribution to journalArticle

Paradise, Jan E. ; Nemorofsky, Deborah ; Huggins, George R. ; Sondheimer, Steven J. ; Plotkin, Stanley A. / Intranasal administration of RA 27/3 rubella virus vaccine. A clinical trial in young adults. In: Journal of Adolescent Health Care. 1984 ; Vol. 5, No. 2. pp. 75-78.
@article{135617a65cae479fa2b9373fa389efdf,
title = "Intranasal administration of RA 27/3 rubella virus vaccine. A clinical trial in young adults",
abstract = "Of the vaccines and inoculation routes studied for the prevention of rubella, only the RA27/3 vaccine, administered intranasally, has the ability to stimulate a humoral antibody pattern very similar to that evoked by wild rubella infection. Because information about intranasal (IN) vaccination has only been obtained using the RA 27/3 vaccine manufactured in Europe, we conducted a trial of IN vaccination among young adults using Meruvax II which is manufactured in the USA. Of 597 family planning clinic patients screened in 1980-1981, 71 (11.9{\%}) were susceptible to rubella; forty-one subjects were randomly assigned to receive IN or subcutaneous (SC) vaccine. All 20 SC vaccinees, but only 8/21 (38{\%}) IN vaccinees, were successfully immunized. We conclude that standard doses of commercially available RA 27/3 vaccine are insufficient for IN immunization against rubella. Additional study of the dose-response relationship is needed if IN vaccination is to be recommended.",
keywords = "Immunization, Rubella prevention and control, Rubella vaccine",
author = "Paradise, {Jan E.} and Deborah Nemorofsky and Huggins, {George R.} and Sondheimer, {Steven J.} and Plotkin, {Stanley A.}",
year = "1984",
doi = "10.1016/S0197-0070(84)80002-9",
language = "English (US)",
volume = "5",
pages = "75--78",
journal = "Journal of Adolescent Health",
issn = "1054-139X",
publisher = "Elsevier USA",
number = "2",

}

TY - JOUR

T1 - Intranasal administration of RA 27/3 rubella virus vaccine. A clinical trial in young adults

AU - Paradise, Jan E.

AU - Nemorofsky, Deborah

AU - Huggins, George R.

AU - Sondheimer, Steven J.

AU - Plotkin, Stanley A.

PY - 1984

Y1 - 1984

N2 - Of the vaccines and inoculation routes studied for the prevention of rubella, only the RA27/3 vaccine, administered intranasally, has the ability to stimulate a humoral antibody pattern very similar to that evoked by wild rubella infection. Because information about intranasal (IN) vaccination has only been obtained using the RA 27/3 vaccine manufactured in Europe, we conducted a trial of IN vaccination among young adults using Meruvax II which is manufactured in the USA. Of 597 family planning clinic patients screened in 1980-1981, 71 (11.9%) were susceptible to rubella; forty-one subjects were randomly assigned to receive IN or subcutaneous (SC) vaccine. All 20 SC vaccinees, but only 8/21 (38%) IN vaccinees, were successfully immunized. We conclude that standard doses of commercially available RA 27/3 vaccine are insufficient for IN immunization against rubella. Additional study of the dose-response relationship is needed if IN vaccination is to be recommended.

AB - Of the vaccines and inoculation routes studied for the prevention of rubella, only the RA27/3 vaccine, administered intranasally, has the ability to stimulate a humoral antibody pattern very similar to that evoked by wild rubella infection. Because information about intranasal (IN) vaccination has only been obtained using the RA 27/3 vaccine manufactured in Europe, we conducted a trial of IN vaccination among young adults using Meruvax II which is manufactured in the USA. Of 597 family planning clinic patients screened in 1980-1981, 71 (11.9%) were susceptible to rubella; forty-one subjects were randomly assigned to receive IN or subcutaneous (SC) vaccine. All 20 SC vaccinees, but only 8/21 (38%) IN vaccinees, were successfully immunized. We conclude that standard doses of commercially available RA 27/3 vaccine are insufficient for IN immunization against rubella. Additional study of the dose-response relationship is needed if IN vaccination is to be recommended.

KW - Immunization

KW - Rubella prevention and control

KW - Rubella vaccine

UR - http://www.scopus.com/inward/record.url?scp=0021273487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021273487&partnerID=8YFLogxK

U2 - 10.1016/S0197-0070(84)80002-9

DO - 10.1016/S0197-0070(84)80002-9

M3 - Article

C2 - 6368506

AN - SCOPUS:0021273487

VL - 5

SP - 75

EP - 78

JO - Journal of Adolescent Health

JF - Journal of Adolescent Health

SN - 1054-139X

IS - 2

ER -